CNCR stock forecast, quote, news & analysis

The most notable companies in this group are Merck & Co (NYSE:MRK), Bristol-Myers Squibb Co (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), Exelixis (NASDAQ:EXEL).

The investment seeks to track the performance, before fees and expenses, of the Range Oncology Therapeutics Index. The index was established in 2023 by Range Fund Holdings and tracks the performance of a portfolio of U.S. exchange-listed pharmaceutical or biotechnology stocks or American Depositary Receipts (“ADRs”) with a market capitalization of more than $250 million. The advisor attempts to invest all, or substantially all, of its assets in the component securities that make up the index. Under normal circumstances, at least 80% of the fund’s total assets will be invested in the component securities of the index.

The average market capitalization across the Range Cancer Therapeutics ETF ETF is 8.96B. The market cap for tickers in the group ranges from 10.12M to 331.75B. MRK holds the highest valuation in this group at 331.75B. The lowest valued company is APLM at 10.12M.

The average weekly price growth across all stocks in the Range Cancer Therapeutics ETF ETF was 1%. For the same ETF, the average monthly price growth was -9%, and the average quarterly price growth was -7%. REPL experienced the highest price growth at 38%, while KURA experienced the biggest fall at -32%.

The average weekly volume growth across all stocks in the Range Cancer Therapeutics ETF ETF was -23%. For the same stocks of the ETF, the average monthly volume growth was 69% and the average quarterly volume growth was 22%